MSFT 414.2 2.0901% AAPL 220.11 -0.3621% NVDA 108.1 1.5309% GOOGL 148.66 -0.0336% GOOG 150.01 0.3143% AMZN 179.55 2.366% META 504.79 0.0% AVGO 148.21 5.2478% TSLA 226.17 4.5776% TSM 162.43 -0.215% LLY 901.25 -0.7729% V 285.34 -0.0945% JPM 205.56 -5.1889% UNH 599.03 0.8298% NVO 129.78 -1.6147% WMT 78.81 1.9007% LVMUY 135.45 -0.7401% XOM 110.82 -3.6432% LVMHF 676.0 -1.0402% MA 488.02 0.1909%
Last update at 2024-09-10T20:01:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -108.12200M | -57.94300M | -51.97200M | - |
| Minority interest | - | - | - | - |
| Net income | -108.17600M | -58.23500M | -51.86400M | - |
| Selling general administrative | 30.02M | 17.60M | 9.87M | - |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 24.86M | 37.04M | 7.66M | - |
| Reconciled depreciation | 1.61M | 0.90M | 0.72M | - |
| Ebit | -112.67900M | -59.08700M | -52.20000M | -15.16200M |
| Ebitda | -111.07100M | -58.19000M | -51.48200M | - |
| Depreciation and amortization | 1.61M | 0.90M | 0.72M | - |
| Non operating income net other | -1.44700M | -1.03000M | - | - |
| Operating income | -111.07100M | -58.19000M | -52.20000M | - |
| Other operating expenses | 135.93M | 95.23M | 59.86M | - |
| Interest expense | 2.95M | 1.14M | 0.00000M | 0.00000M |
| Tax provision | 0.05M | 0.29M | 0.00000M | - |
| Interest income | 1.46M | 0.49M | 0.11M | - |
| Net interest income | 1.46M | 0.49M | 0.11M | - |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | 0.05M | 0.29M | -0.10800M | - |
| Total revenue | 24.86M | 37.04M | 7.66M | - |
| Total operating expenses | 135.93M | 95.23M | 59.86M | - |
| Cost of revenue | - | - | - | - |
| Total other income expense net | 2.95M | 0.25M | 0.23M | - |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -108.17600M | -58.23500M | -51.97200M | - |
| Net income applicable to common shares | -108.17600M | -58.23500M | -51.97200M | -14.09500M |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 402.57M | 436.47M | 500.15M | 207.25M | - |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 8.80M | 6.57M | 4.52M | 1.31M | - |
| Total liab | 149.46M | 186.99M | 155.41M | 168.65M | - |
| Total stockholder equity | 253.11M | 249.48M | 344.75M | 38.60M | - |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 15.40M | 17.53M | 9.94M | 6.14M | 19.93M |
| Common stock | 0.10M | 0.09M | 0.09M | 0.04M | 0.01M |
| Capital stock | 0.10M | 0.09M | 0.09M | 0.04M | - |
| Retained earnings | -371.25600M | -269.51200M | -161.33600M | -103.10100M | -51.12900M |
| Other liab | - | - | 114.72M | 120.81M | 14.12M |
| Good will | - | - | - | - | - |
| Other assets | - | - | 1.73M | 166.82M | 2.28M |
| Cash | 66.39M | 59.97M | 142.75M | 28.38M | - |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 45.94M | 55.55M | 40.69M | 40.92M | 25.85M |
| Current deferred revenue | 25.67M | 31.79M | 26.02M | 31.98M | - |
| Net debt | -27.46500M | -18.83700M | -141.24200M | -20.49700M | - |
| Short term debt | 2.08M | 1.77M | 1.50M | 0.96M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 38.92M | 41.13M | 1.50M | 7.88M | - |
| Other stockholder equity | 624.08M | 522.61M | 506.76M | 141.64M | 0.01000M |
| Property plant equipment | - | 10.88M | 6.09M | 11.30M | 11.83M |
| Total current assets | 346.54M | 375.27M | 492.34M | 193.63M | 41.66M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 249.48M | 344.75M | -97.94400M | -47.79500M |
| Short term investments | 270.50M | 306.17M | 342.51M | 161.94M | - |
| Net receivables | 0.00000M | 2.00M | 2.00M | 2.00M | - |
| Long term debt | - | - | - | - | - |
| Inventory | - | 0.57M | 0.57M | - | - |
| Accounts payable | 2.79M | 4.45M | 3.23M | 1.84M | 0.67M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.19M | -3.70500M | -0.76500M | 0.02M | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.09M | 0.09M | 157.36M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -269.51200M | -161.33600M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.61M | 3.43M | 1.73M | 2.32M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 56.03M | 61.20M | 7.82M | 13.62M | - |
| Capital lease obligations | 38.92M | 41.13M | 1.50M | 7.88M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 34.09M | -181.59700M | -144.32000M | 2.67M |
| Change to liabilities | -8.13400M | -10.81000M | 120.25M | -15.22500M |
| Total cashflows from investing activities | 26.40M | -183.43400M | -145.46600M | 0.85M |
| Net borrowings | - | - | - | - |
| Total cash from financing activities | 1.61M | 357.32M | 80.88M | 11.00M |
| Change to operating activities | - | -0.53500M | 0.42M | 1.70M |
| Net income | -108.17600M | -58.23500M | -51.97200M | -14.09500M |
| Change in cash | -81.06600M | 114.36M | 5.49M | -12.95500M |
| Begin period cash flow | 145.02M | 30.66M | 25.17M | - |
| End period cash flow | 63.96M | 145.02M | 30.66M | 25.17M |
| Total cash from operating activities | -109.08000M | -59.52700M | 70.07M | -24.80300M |
| Issuance of capital stock | 0.00000M | 29.99M | 80.84M | - |
| Depreciation | 1.61M | 0.90M | 0.72M | 0.64M |
| Other cashflows from investing activities | - | - | -0.04000M | -0.04000M |
| Dividends paid | - | - | - | - |
| Change to inventory | - | - | 0.42M | - |
| Change to account receivables | - | 0.00000M | -2.00000M | -2.00000M |
| Sale purchase of stock | - | 31.05M | - | - |
| Other cashflows from financing activities | -0.00800M | 327.33M | -145.46600M | 326.28M |
| Change to netincome | 13.56M | 9.16M | 2.65M | 2.18M |
| Capital expenditures | 7.69M | 1.84M | 1.11M | 1.82M |
| Change receivables | - | - | - | - |
| Cash flows other operating | -7.93900M | -3.29500M | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | -81.06600M | 114.36M | - | - |
| Change in working capital | -18.49300M | -11.34500M | 118.67M | - |
| Stock based compensation | 14.23M | 7.83M | 1.76M | - |
| Other non cash items | 1.75M | 1.32M | 0.89M | - |
| Free cash flow | -116.77200M | -61.36400M | 68.97M | - |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics Inc |
-0.07 0.76% | 9.09 | - | - | 21.50 | 3.10 | 13.35 | -4.3619 |
| NVO Novo Nordisk A/S |
-2.13 1.61% | 129.78 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 128.64 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.33 0.07% | 470.78 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-8.42 0.74% | 1136.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
201 Brookline Avenue, Boston, MA, United States, 02215
| Name | Title | Year Born |
|---|---|---|
| Dr. Barbara L. Weber M.D. | Pres, CEO & Director | 1956 |
| Ms. Daniella Beckman CPA | Chief Financial Officer | 1979 |
| Dr. Alan Huang Ph.D. | Chief Scientific Officer | 1973 |
| Dr. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board | 1961 |
| Dr. Levi Garraway M.D., Ph.D. | Founder | NA |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board | 1958 |
| Dr. Timothy K. Lu M.D., Ph.D. | Founder | 1981 |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 1967 |
| Mr. Douglas J. Barry Esq., J.D. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | 1970 |
| Mr. John C. Ross M.S. | VP of HR | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...